Last updated: May 1, 2026
What is VERELAN PM and what is its commercial positioning?
VERELAN PM is an extended-release formulation of verapamil hydrochloride marketed for cardiovascular indications associated with calcium-channel blockade (commonly hypertension and chronic stable angina). The product name “VERELAN PM” refers to the brand’s “night-time” extended-release regimen; the underlying active ingredient is verapamil HCl.
From a patent perspective, VERELAN PM is a legacy small-molecule product with an established regulatory and commercial history, and the market is primarily driven by (1) ongoing generic competition, (2) formulary access, and (3) pricing behavior in the US and key ex-US markets.
What is the latest clinical trials landscape for verapamil extended-release products?
No sufficient, decision-grade, product-specific clinical-trial updates for VERELAN PM (brand-specific) can be produced from the information available in this request. A complete trials update requires brand-specific inclusion in registries (e.g., ClinicalTrials.gov entries that explicitly match “VERELAN PM” rather than generic “verapamil ER”), along with dates, study phase, endpoints, and outcomes. Without that, any “update” would be non-actionable and not correctly attributable to VERELAN PM.
How should investors and business teams frame the competitive and regulatory market dynamics?
Because verapamil is off-patent in most jurisdictions and is widely available as generics, VERELAN PM’s commercial outcomes typically track the following structural drivers:
-
Generic penetration and price compression
- Once generic equivalents exist, brand volumes usually decline unless formulary restrictions or payer-specific preferences maintain a niche position.
-
Formulary and payer channel control
- Use is shaped by preferred-drug lists for calcium-channel blockers and by interchangeability policies.
-
Supply chain reliability and NDC-level competition
- Brand performance depends on the stability of supply and the intensity of competing immediate-release and extended-release verapamil SKUs.
-
Safety and prescribing behavior
- Verapamil therapy is constrained by contraindications and monitoring patterns (e.g., conduction abnormalities), which affects adoption more than “new efficacy” claims would for an on-patent drug.
What is the current market outlook and how does it translate into projections?
A quantitative market projection for VERELAN PM requires current revenue baselines (by geography and channel), competitive pricing and volume data, and an explicit methodology (TAM/SAM/SOM, time horizon, and scenario set). This request provides none of those inputs, and the required brand-specific market figures are not present in the information available here.
Therefore, a complete and accurate market analysis with projections cannot be produced.
Decision-grade projection framework (non-quantified) for VERELAN PM
Even without numeric projections, business teams can map likely directional outcomes using a standard projection tree that applies to legacy generic-exposed products:
- Base case direction: low growth or continued erosion driven by ongoing generic substitutions and periodic payer tightening.
- Upside case direction: stabilization if:
- a limited number of long-acting verapamil ER SKUs dominate preferred lists,
- contract pricing sustains brand economics,
- and channel inventory cycles reduce switch rates.
- Downside case direction: volume and revenue decline if:
- additional low-cost generics enter or gain formulary placement,
- payers move to lower-cost alternatives within the same therapeutic class,
- or supply constraints shift prescriptions toward competing ER brands/SKUs.
This framework is directional only; it does not provide numeric forecasts.
Key takeaways
- VERELAN PM is a verapamil hydrochloride extended-release brand whose market performance is largely determined by generic competition, formulary access, and pricing behavior, not by novel clinical differentiation.
- A decision-grade “clinical trials update” specifically for VERELAN PM cannot be completed from the available request data because it requires brand-specific trial registry evidence (dates, phases, endpoints, and outcomes).
- A decision-grade quantitative market analysis and numeric projections cannot be produced without current brand baseline metrics and explicit market sizing inputs.
FAQs
-
Is VERELAN PM still under active clinical development as a brand?
Brand-specific active development must be evidenced by trials that explicitly list VERELAN PM (or its proprietary formulation) and provide current enrollment status, endpoints, and results. Those data are not present here.
-
What drives VERELAN PM sales most in practice?
Generic substitution risk, payer formulary positioning for calcium-channel blockers, contract pricing, and adherence to extended-release verapamil prescribing patterns.
-
Can verapamil ER trials be used as a substitute for VERELAN PM-specific updates?
Only when the trial formulation matches the specific brand regimen and is explicitly comparable. Without that mapping, results cannot be attributed to VERELAN PM.
-
What is the typical lifecycle risk profile for legacy verapamil ER brands?
Ongoing price erosion under generic competition and periodic payer preference shifts within the therapeutic class.
-
What would make a numeric market projection credible for VERELAN PM?
A validated baseline (revenue/units by geography), current competitive set at NDC/packaging level, and a scenario-based model tied to payer and pricing trends.
References
[1] U.S. National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/
[2] FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
[3] FDA Labeling (Drugs@FDA). https://www.accessdata.fda.gov/scripts/cder/daf/
